PULMONARY HYPERTENSION is a severe medical condition, which is hard to detect reliably in its early stages when it is easier to treat. This complex pathology affects the pulmonary vasculature and the right heart, with many potential innovations in diagnosis and target therapy. Evaluating its severity requires many stratification tools, multiparametric risk factors including functional class, exercise capacity, biochemical variables, echocardiographic and other imaging data, and mainly a full hemodynamics characterization which is the gold despite its invasiveness standard to diagnose this disease finally. In recent years, the importance of non-invasive imaging-based diagnostic tools both for the characterization of vascular dysfunction and the impact on the function of the right ventricle has been significantly increasing. This presentation will show the current state of the imaging-based diagnostic field and some of the Molecular and Functional Biomarkers research group's results in preclinical models and clinical studies.

You can join the seminar at: https://rediris.zoom.us/j/82509445673?pwd=VE9xaVdydCtmbHVBUjdobkpyb0ZnZz09